-
Mashup Score: 0The Impact of Darolutamide on Dose Modification of mHSPC - 11 month(s) ago
Arash Rezazadeh Kalebasty, MD, discusses the dose modification impact of the addition of darolutamide for patients with metastatic hormone sensitive prostate cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Brenda Martone Highlights Nursing Considerations With Darolutamide in Prostate Cancer - 11 month(s) ago
Brenda Martone MSN, ANP-BC, AOCNP, discusses what nurses need to know about safely treating patients with darolutamide.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Brenda Martone MSN, ANP-BC, AOCNP, discusses what nurses need to know about safely treating patients with darolutamide. #darolutamide #Oncology #pcsm #prostatecancer #ONSCongress @NorthwesternMed full interview: https://t.co/CtoxbQdWOx https://t.co/pca45wsc81
-
-
Mashup Score: 0Brenda Martone Highlights Nursing Considerations With Darolutamide in Prostate Cancer - 11 month(s) ago
Brenda Martone MSN, ANP-BC, AOCNP, discusses what nurses need to know about safely treating patients with darolutamide.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Brenda Martone MSN, ANP-BC, AOCNP, discusses what nurses need to know about safely treating patients with darolutamide. #darolutamide #Oncology #pcsm #prostatecancer #ONSCongress @NorthwesternMed full interview: https://t.co/rVu49osRO8 https://t.co/e0dQyhP5en
-
-
Mashup Score: 1Brenda Martone Highlights Nursing Considerations With Darolutamide in Prostate Cancer - 11 month(s) ago
Brenda Martone MSN, ANP-BC, AOCNP, discusses what nurses need to know about safely treating patients with darolutamide.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Watch Now! Brenda Martone Highlights Nursing Considerations With Darolutamide in Prostate Cancer #darolutamide #Oncology #pcsm #prostatecancer #ONSCongress @NorthwesternMed https://t.co/ADMkBcpKKr https://t.co/3lubIXYycl
-
-
Mashup Score: 2
Neal Shore, MD, discusses the long-term exposure analysis of darolutamide in the phase 3 ARAMIS Rollover trial for patients with nonmetastatic castration-resistant prostate cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Neal Shore, MD, discusses the long-term exposure analysis of #darolutamide in the phase 3 ARAMIS rollover trial for patients with nonmetastatic castration-resistant #prostatecancer. #pcsm #mcrpc | @GenesisCare https://t.co/rt9tChuxu0
-
-
Mashup Score: 0Arash Rezazadeh Kalebasty Discusses Darolutamide Combination Safety in the ARASENS Study - 1 year(s) ago
Arash Rezazadeh Kalebasty, MD, discusses the rates of dose reduction and treatment discontinuation for patients with hormone-sensitive prostate cancer receiving combination therapy with darolutamide.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Arash Rezazadeh Kalebasty, MD, discusses the rates of dose reduction and treatment discontinuation for patients with hormone-sensitive #prostatecancer receiving combination therapy with darolutamide. #pcsm #oncology #nursing #darolutamide Watch: https://t.co/UmdC17Uh6h https://t.co/K9gjlvV7U7
-
-
Mashup Score: 0Arash Rezazadeh Kalebasty Discusses Darolutamide Combination Safety in the ARASENS Study - 1 year(s) ago
Arash Rezazadeh Kalebasty, MD, discusses the rates of dose reduction and treatment discontinuation for patients with hormone-sensitive prostate cancer receiving combination therapy with darolutamide.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Arash Rezazadeh Kalebasty Discusses Darolutamide Combination Safety in the ARASENS Study #prostatecancer #pcsm #oncology #nursing #darolutamide https://t.co/yppi8NSjHh https://t.co/WB5InPLNc4
-
-
Mashup Score: 0darolutamide | CADTH - 1 year(s) ago
( Last Updated : December 1, 2022) Generic Name: darolutamide …
Source: www.cadth.caCategories: Latest Headlines, UrologyTweet-
Triplet therapy with #darolutamide and docetaxel moving from trial data to routine practice in Canada with positive review from CADTH: https://t.co/74fPybGMGJ @CanUrolAssoc @UroOncMD @DrAndrewLoblaw @aleberlin2
-
-
Mashup Score: 0
Darolutamide, sold as Nubeqa, is an androgen receptor inhibitor, which works to limit prostate cell growth by preventing the binding of hormones, or androgens, to proteins known as androgen receptors.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
#FDA Approves #Darolutamide Combo for Metastatic Hormone-Sensitive #ProstateCancer https://t.co/86xbVTbaTT https://t.co/dYKHrvadOz
-
-
Mashup Score: 0
The FDA has accepted a supplemental new drug application for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer and granted it priority review.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The #FDA has accepted a supplemental new drug application for #darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer and granted it priority review. #pcsm #oncology https://t.co/qTL7Z11rIT
-
In this video, Arash Rezazadeh Kalebasty, MD, discusses the dose modification impact of adding #darolutamide in metastatic hormone-sensitive prostate cancer. #pcsm | @UCIrvineHealth https://t.co/tYNkkyFQDZ